Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Gepersonaliseerde preventie en behandeling van hersenmetastasen
nov 2022 | Immuuntherapie, Longoncologie, Radiotherapie